HOME >> BIOLOGY >> NEWS
Stronger therapy better for AML with normal genetics

COLUMBUS, Ohio New research is helping select which therapies improve the chances of remission in the largest category of people affected by acute myeloid leukemia (AML) those whose cancer cells have normal-looking chromosomes.

The findings suggest that people receiving more intense therapies are more likely to enter remission and to remain there longer than those receiving lower-dose therapies.

The study was published online Nov. 8 by the Journal of Clinical Oncology.

The Cancer and Leukemia Group B (CALGB) study was initiated by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSU CCC-James). It is part of a larger CALGB cytogenetic trial chaired by Clara D. Bloomfield, professor of internal medicine and the William G. Pace III Professor in Cancer Research, OSU Cancer Scholar and senior adviser to the OSU cancer program.

Unexpectedly, the current study also found that patients who had an enlarged spleen at the time of their initial treatment were less likely to enter remission. AML patients are in remission when leukemic cells are not microscopically detectable among their bone-marrow cells.

"These preliminary findings raise the question of whether additional treatment directed specifically to the spleen might improve remission rates," says first author Sherif S. Farag, assistant professor of internal medicine and a medical oncologist with the OSU CCC-James. "At this point, this is just a hypothesis that needs to be tested, but it may be that the spleen is a sanctuary site for leukemic cells and needs separate treatment."

A diagnosis of AML routinely includes studying patients' leukemic cells for chromosome damage, a process known as cytogenetic analysis. The information helps determine the best therapy and a patient's chance of remission and cure. But 40 percent of AML patients have leukemic cells wit
'"/>

Contact: Darrell E. Ward
Ward-15@medctr.osu.edu
614-293-3737
Ohio State University
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Stronger evidence found linking Epstein-Barr virus and risk of multiple sclerosis
2. Testosterone replacement therapy: How safe for aging men?
3. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
4. Aggressive therapy best for certain AML patients
5. Under magnetic force, nanoparticles may deliver gene therapy
6. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Stem cell therapy rescues motor neurons in ALS model
8. Study identifies new gene therapy tools for inherited blindness
9. Breast cancer and hormone therapy -- A looking-glass mirror?
10. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
11. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/3/2019)... ... October 02, 2019 , ... Personalized Stem Cells, ... patient in an FDA approved clinical trial for stem cell treatment of knee ... formation of the company as a subsidiary of VetStem Biopharma. , PSC CEO, Michael ...
(Date:9/30/2019)... ... September 30, 2019 , ... ... mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent ... product formats (patent number AU 2015259373). This new patent adds intellectual property ...
(Date:9/25/2019)... ... , ... Deep Science Ventures (DSV), a new paradigm for applied ... of cancer research. , Deep Science Ventures was founded to create a better method ... from the start, both at the industry and biological level. , Through their ...
Breaking Biology News(10 mins):
(Date:9/30/2019)... (PRWEB) , ... September 30, 2019 , ... ... materials science newsletter from Rigaku Corporation , is now available online on ... to X-ray based materials science, including X-ray diffraction, fluorescence and imaging, and presents ...
(Date:9/24/2019)... (PRWEB) , ... September 24, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... a clinical-stage biopharmaceutical company focused on the development of therapies to treat ...
(Date:9/24/2019)... ... , ... In the past three years, the National Science Foundation (NSF) has ... School of Mines & Technology that expands human understanding of the microbial world. ... slimy and yet strong layer which is commonly known as a biofilm. , The ...
(Date:9/17/2019)... ... 2019 , ... Tucker, a Labrador retriever, was just a puppy when he ... and lame on his right hip and elbow. At one year of age, Tucker ... case the vet had seen.” He was prescribed pain medications, both oral and injectable, ...
Breaking Biology Technology:
Cached News: